ATE466937T1 - Verfahren zum nachweis von leberkrebs, diagnostikum für leberkrebs sowie heilmittel gegen krebs - Google Patents

Verfahren zum nachweis von leberkrebs, diagnostikum für leberkrebs sowie heilmittel gegen krebs

Info

Publication number
ATE466937T1
ATE466937T1 AT04819413T AT04819413T ATE466937T1 AT E466937 T1 ATE466937 T1 AT E466937T1 AT 04819413 T AT04819413 T AT 04819413T AT 04819413 T AT04819413 T AT 04819413T AT E466937 T1 ATE466937 T1 AT E466937T1
Authority
AT
Austria
Prior art keywords
cancer
liver cancer
dlk
detecting liver
antibody
Prior art date
Application number
AT04819413T
Other languages
English (en)
Inventor
Koji Nakamura
Hiroko Anzai
Hiroyuki Yanai
Atsushi Miyajima
Original Assignee
Kanagawa Kagaku Gijutsu Akad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanagawa Kagaku Gijutsu Akad filed Critical Kanagawa Kagaku Gijutsu Akad
Application granted granted Critical
Publication of ATE466937T1 publication Critical patent/ATE466937T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT04819413T 2003-11-28 2004-11-25 Verfahren zum nachweis von leberkrebs, diagnostikum für leberkrebs sowie heilmittel gegen krebs ATE466937T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2003399331 2003-11-28
JP2003401585 2003-12-01
JP2003423237 2003-12-19
PCT/JP2004/017499 WO2005052156A1 (ja) 2003-11-28 2004-11-25 肝癌の検出方法及び肝癌診断薬並びに癌治療薬

Publications (1)

Publication Number Publication Date
ATE466937T1 true ATE466937T1 (de) 2010-05-15

Family

ID=34636972

Family Applications (2)

Application Number Title Priority Date Filing Date
AT10003331T ATE546527T1 (de) 2003-11-28 2004-11-25 Verfahren zum nachweis von leberkrebs, diagnose auf leberkrebs und heilmittel gegen krebs
AT04819413T ATE466937T1 (de) 2003-11-28 2004-11-25 Verfahren zum nachweis von leberkrebs, diagnostikum für leberkrebs sowie heilmittel gegen krebs

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT10003331T ATE546527T1 (de) 2003-11-28 2004-11-25 Verfahren zum nachweis von leberkrebs, diagnose auf leberkrebs und heilmittel gegen krebs

Country Status (8)

Country Link
US (2) US20080112956A1 (de)
EP (2) EP2204448B1 (de)
JP (1) JP4695982B2 (de)
AT (2) ATE546527T1 (de)
CA (1) CA2552553C (de)
DE (1) DE602004027085D1 (de)
ES (2) ES2382987T3 (de)
WO (1) WO2005052156A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008056833A1 (en) 2006-11-10 2008-05-15 Livtech Inc. ANTI-HUMAN Dlk-1 ANTIBODY SHOWING ANTI-TUMOR ACTIVITY IN VIVO
WO2009116670A1 (ja) 2008-03-17 2009-09-24 株式会社リブテック in vivoで抗腫瘍活性を有する抗ヒトDlk-1抗体
KR100964193B1 (ko) * 2009-04-17 2010-06-16 씨비에스바이오사이언스 주식회사 간암 예후 마커
EA201500220A1 (ru) 2010-05-17 2015-10-30 Ливтех, Инк. Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
EP2412792A1 (de) 2010-07-29 2012-02-01 The Procter & Gamble Company Flüssige Reinigungsmittelzusammensetzung
WO2012138100A2 (ko) * 2011-04-04 2012-10-11 한국생명공학연구원 Dlk1 세포 외 수용성 도메인을 포함하는 액티빈 수용체 타입 2b 억제제
WO2012138102A2 (ko) * 2011-04-04 2012-10-11 한국생명공학연구원 Dlk1 특이적 인간 항체 및 이를 포함하는 약학적 조성물
CN102778566B (zh) * 2011-05-07 2016-01-13 上海市肿瘤研究所 Dlk1在肝癌诊断及预后判断中的应用
US9427464B2 (en) 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
AU2013325443B2 (en) 2012-10-03 2019-01-31 Livtech, Inc. Anti-hDlk-1 antibody having an anti-tumor activity in vivo
RS58400B1 (sr) 2014-05-15 2019-04-30 Eisai R&D Man Co Ltd Jedinjenja pladienolid piridina i postupci primene
IL259198B2 (en) 2015-11-18 2023-04-01 Eisai R&D Man Co Ltd A solid form of paladinolide pyridine compound and methods of its use
CN110031629B (zh) * 2018-01-11 2020-08-18 上海交通大学 检测人血清dlk1蛋白的elisa试剂盒及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0673390T3 (da) * 1992-12-11 2000-11-13 Us Gov Health & Human Serv Deltalignende gen, som udtrykkes i neuroendokrine tumorer
US20030185815A1 (en) * 2001-04-03 2003-10-02 Muralidhara Padigaru Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
JP4344231B2 (ja) * 2001-05-16 2009-10-14 財団法人神奈川科学技術アカデミー dlkを用いた未分化肝細胞の検出及び分離方法
US7189507B2 (en) * 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
CA2500687A1 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003298786A1 (en) * 2002-11-26 2004-06-18 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators

Also Published As

Publication number Publication date
ES2382987T3 (es) 2012-06-15
ATE546527T1 (de) 2012-03-15
EP1702982A4 (de) 2007-04-25
JP4695982B2 (ja) 2011-06-08
EP2204448B1 (de) 2012-02-22
ES2345493T3 (es) 2010-09-24
EP2204448A1 (de) 2010-07-07
CA2552553A1 (en) 2005-06-09
JPWO2005052156A1 (ja) 2007-12-06
DE602004027085D1 (de) 2010-06-17
US20100151503A1 (en) 2010-06-17
US20080112956A1 (en) 2008-05-15
EP1702982B1 (de) 2010-05-05
WO2005052156A1 (ja) 2005-06-09
EP1702982A1 (de) 2006-09-20
CA2552553C (en) 2015-01-06

Similar Documents

Publication Publication Date Title
ATE546527T1 (de) Verfahren zum nachweis von leberkrebs, diagnose auf leberkrebs und heilmittel gegen krebs
DE602005013225D1 (de) Aptamer-nanopartikelkonjugate und verwendungsverfahren zur detektion von zielanalyten
IL287810A (en) Kits for detecting one or more target nucleic acid analytes in a sample and methods of making and using the same
WO2010033371A3 (en) Molecular markers for lung and colorectal carcinomas
WO2007075675A3 (en) High precision code plates and geophones
DK2073008T3 (da) Forbedrede immunoassayfremgangsmåder
Früh et al. Strain field self-diagnostic poly (dimethylsiloxane) elastomers
WO2008111464A1 (ja) スプライシング異常を指標とする抗ガン剤の作用検定方法
ATE541054T1 (de) Bio-barcode erkennung für zielmoleküle
DE602005013998D1 (de) Verfahren und reagenzien zur erkennung von melanomen
WO2006002243A3 (en) Methods of oligosaccharide profiling for the detection of cancer
WO2007105047A3 (en) Ultrasound molecular sensors and uses thereof
Dong et al. DNA walker-powered SERS logic aptasensors for accurate imaging and identification of tumor cells
WO2008108873A3 (en) Molecular biosensors for detecting macromolecules and other analytes
DE602006013333D1 (de) Kit und verfahren zum nachweis von urothelkarzinom
ATE414701T1 (de) Fluoreszenzsonden zur verwendung bei einem bindungsassay auf proteinkinaseinhibitoren
WO2007092664A3 (en) Blocker reagent for reduction of heterophile interferences
DE60329861D1 (de) Neue, auf der antigen-antikörper-reaktion beruhende sondenplatte sowie reagenzienkit und verfahren mit verwendung der sondenplatte
ATE511636T1 (de) Verfahren zum nachweis biologischer organismen mittels raman-streuung
ATE529746T1 (de) Zusammensetzung und verfahren zum nachweis von analyten über eine polymerisierungsbasierte signalverstärkung
CY1113013T1 (el) Βελτιωμενες μεθοδοι ανοσολογικων δοκιμασιων
WO2009016718A1 (ja) 診断薬及びそれを用いた診断方法
DE50113987D1 (de) Verfahren zum Nachweis biologischer Moleküle
DE60139314D1 (de) Verfahren zum prüfen von mit wt1-verbundenen krankheiten
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties